iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Piramal Pharma’s Canada unit gets NAI from USFDA

2 Jun 2025 , 03:18 PM

Piramal Pharma Limited’s shares gained in Monday morning session after the company announced that the United States Food and Drug Administration (USFDA) issued a form 483 with zero observations and no action indicated (NAI) for its Aurora facility in Canada.

However, later in the day, the counter erased early morning gains.

At around 3.11 PM, Piramal Pharma was trading 0.23% lower at ₹205.82, against the previous close of ₹206.30 on NSE. The counter touched an intraday high and low of ₹209.40, and ₹205.10, respectively.

The inspections were conducted by USFDA at the Canada facility between May 26 and May 30.

The company stated in its filing with the bourses that its remains committed to maintain highest compliance standards.

Additionally, the pharma company expects to pace up for meeting its 2030 revenue and margin targets. This comes when near-term uncertainty hovers the biotech funding environment.

The Company’s Chairperson also addressed that while its early-stage funding remains uneven, last-stage clinical development services demand continues to hold-up well.

The business said that its net profit for the quarter ended March 2025 registered a 51.50% growth. It reported a net profit of ₹153.50 Crore. In the previous corresponding quarter, the business posted a net profit of ₹101.30 Crore.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Piramal Pharma
  • Piramal Pharma approval
  • Piramal Pharma News
  • Piramal Pharma Share
  • Piramal Pharma Share Price
  • Piramal Pharma Stock
  • Piramal Pharma Stock Today
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.